Cancer.Net Specialty Editor: Leukemia
The University of Texas MD Anderson Cancer Center
Dr. Naveen Pemmaraju is an Associate Professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston, Texas.
Dr. Pemmaraju received his medical degree in Medical Sciences from the University of Arkansas in Little Rock. He completed his internal medicine training in the Osler Medical Program at Johns Hopkins Hospital in Baltimore, Maryland, followed by a fellowship in hematology and oncology at MD Anderson Cancer Center.
Dr. Pemmaraju’s clinical and research work focuses on improving outcomes and developing novel therapies and clinical trials for patients with acute myeloid leukemia, chronic myeloid leukemia, myeloproliferative neoplasms (MPN), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Pemmaraju serves as principal investigator for several national clinical trials in MPN and BPDCN, and he has helped develop novel targeted therapies for patients with these disorders. He led a multicenter team in a phase 1 and phase 2 clinical trial for patients with BPDCN that ultimately led to FDA approval for the first targeted agent available for this rare leukemia.
Dr. Pemmaraju is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research. He serves as a section editor for Elsevier, is on the advisory board for Oncology Times, HemOnc Times, and is a reviewer for several medical journals.
Dr. Pemmaraju has authored and/or coauthored more than 185 peer-reviewed articles and has presented his work at both national and international meetings.
View current ASCO disclosure here.
Last updated: February 2020